CDC42 and cancer: To further extend the implications of our findings to the treatment of HPV-related cancers, we then picked out afatinib, a selective epidermal growth factor receptor (EGFR) inhibitor, due to its most positive sensitivity correlation with CDC42 according to analyses results from Cancer Therapeutics Response Portal (CTRP).